GenScript BIO (01548) released its mid-term results, with a shareholder loss of $129 million, narrowing by 29.25% year-on-year.

GENSCRIPT BIO (01548) announced its interim results for the six months ended June 30, 2026, reporting revenue of $404 million, a year-on-year increase of 27.35%. The loss attributable to shareholders was $129 million, a decrease of 29.25% compared to the previous year; the loss per share was 5.92 cents. The announcement stated that the increase in revenue was primarily due to (i) the continuous rise in industry demand for AI-driven drug discovery and antibody drug discovery, accelerating growth in the "gene-to-protein" business; (ii) a strong recovery in upstream demand in the CRDMO industry, driving an increase in project acceptance and improved capacity utilization; and (iii) ongoing expansion in the industrial enzyme business, contributing to steady sales growth during the reporting period.